乳腺放疗后心脏亚结构剂量学与主要不良心脏事件:12年队列及NTCP模型
该多中心回顾性队列纳入633例接受术后放疗的乳腺癌患者,随访中位11.8年,29例(4.6%)发生主要不良心脏事件(MACE)。左前降支(LAD)V40是MACE最强剂量学预测因子,阈值≥18%者风险增加逾2倍,含LAD V40、年龄和心脏病史的NTCP模型区分度优良(校正C指数0.865)。
要点
- LAD V40是乳腺放疗后MACE最强剂量学预测因子,优于全心剂量学。
- NTCP模型含LAD V40、年龄和心脏病史,校正C指数0.865。
核心结论
- LAD V40是乳腺放疗后MACE优于全心剂量学的预测因子,NTCP模型待外部验证后可用于个体化风险分层。
研究设计与样本
- 回顾性多中心队列研究,纳入2011—2013年香港2家公立医院633例接受术后放疗的女性乳腺癌患者。
- 回顾性勾画心脏及6个心脏亚结构,提取剂量体积指标并转换为2 Gy分次等效剂量。
- 主要终点为MACE首次发生,采用Fine-Gray回归(非心源性死亡为竞争事件)筛选预测因子并构建NTCP模型。
主要发现
- 中位随访11.8年,29例(4.6%)发生MACE。
- 最终NTCP模型(含LAD V40、年龄、心脏病史)校正C指数0.865,区分度优良。
- 与3DCRT相比,VMAT再计划高风险病例可大幅降低LAD V40,平均绝对降低 projected 10年超额MACE风险5.7%。
关键数值与推荐
- NTCP模型校正C指数0.865,含LAD V40、年龄和心脏病史。
临床怎么用
- 乳腺放疗计划评估应关注LAD V40而非仅全心剂量学,LAD V40≥18%提示高风险。
- 对高风险患者可考虑VMAT等心脏保护技术以降低LAD V40及10年超额MACE风险。
- NTCP模型可用于个体化风险分层,但需外部验证后推广。
局限性
- 回顾性研究设计,心脏亚结构为回顾性勾画。
- MACE事件数较少(29例),模型需外部验证。
- VMAT再计划的风险降低为模型推算值,非前瞻性验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify cardiac substructure dosimetric predictors of major adverse cardiac events (MACE) following breast radiation therapy (RT), and to develop a robust normal tissue complication probability (NTCP) model for personalized risk assessment using a cohort with over a decade of follow-up. METHODS AND MATERIALS: This retrospective study included 633 female breast cancer patients receiving postoperative RT (2011-2013) at 2 Hong Kong public hospitals. The heart and 6 cardiac substructures were retrospectively contoured on planning computed tomographies, and dose-volume metrics were extracted and converted to equivalent dose in 2 Gy fractions. The primary endpoint was the first occurrence of MACE (cardiogenic death, myocardial infarction, coronary revascularization, unstable angina, or heart failure). Fine-Gray regression was used to identify predictors of MACE, with noncardiogenic death as the competing event. Based on these predictors, an NTCP model was developed to quantify the 10-year excess MACE risk attributable to radiation. Model performance was evaluated using bootstrap optimism-corrected Harrell's C-index and 10-year time-dependent AUC. RESULTS: Over a median follow-up of 11.8 years, 29 patients (4.6%) developed MACE. In multivariable analysis, left anterior descending artery (LAD) V40 in equivalent dose in 2 Gy fractions emerged as the strongest dosimetric predictor (subdistribution hazard ratio, 1.023 per %; P = .010). A threshold of LAD V40 ≥18% identified patients at more than 2-fold increased risk of MACE (subdistribution hazard ratio, 2.333; P = .033). The final NTCP model (incorporating LAD V40, age, and cardiac history) demonstrated excellent discrimination with an optimism-corrected C-index of 0.865. Compared with 3-dimensional conformal RT, volumetric modulated arc therapy replanning of high-risk cases substantially reduced LAD V40, translating to an average 5.7% absolute reduction in projected 10-year excess MACE risk. CONCLUSIONS: In this multicenter cohort with long-term follow-up, LAD V40 was identified as a superior predictor of MACE compared to whole-heart dosimetry. Pending external validation, the developed NTCP model offers a promising framework for personalized risk stratification to guide the use of cardiac-sparing techniques.
引用
- Lui JCF, Chan JCH, Chow JCH, et al. Cardiac Substructure Dosimetry and Major Adverse Cardiac Events After Breast Radiation Therapy: A 12-Year Cohort Study With Normal Tissue Complication Probability Modeling. Int J Radiat Oncol Biol Phys. 2026. PMID: 42373014. doi:10.1016/j.ijrobp.2026.06.3062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。